<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>+G306P703</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName>Kryo Systeme IIa</deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABV7+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-15T17:31:09.648Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P601</udiDi>
    <basicUdiDi>++G306P69Y</basicUdiDi>
    <tradeName>Kryo Systeme I</tradeName>
    <deviceName>Kryo Systeme I</deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Systeme der Consarctic Produktgruppe 1</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-15T17:31:09.539Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P605</udiDi>
    <basicUdiDi>++G306P69Y</basicUdiDi>
    <tradeName>Kryo Systeme I</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Systeme der Consarctic Produktgruppe 5</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.446Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P607</udiDi>
    <basicUdiDi>++G306P69Y</basicUdiDi>
    <tradeName>Kryo Systeme I</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Systeme der Consarctic Produktgruppe 2</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.428Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P608</udiDi>
    <basicUdiDi>++G306P69Y</basicUdiDi>
    <tradeName>Kryo Systeme I</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Systeme der Consarctic Produktgruppe 3</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.410Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P609</udiDi>
    <basicUdiDi>++G306P69Y</basicUdiDi>
    <tradeName>Kryo Systeme I</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Systeme der Consarctic Produktgruppe 4</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.394Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P610</udiDi>
    <basicUdiDi>++G306P69Y</basicUdiDi>
    <tradeName>Kryo Systeme I</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf I</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Mischsysteme bestehend aus Medizinprodukten mehrerer Consarctic Produktgruppen 1 bis 5</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.376Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P704</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABV11+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.336Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P706</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABV13+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.317Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P709</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABV28+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.297Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P713</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABV48+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.281Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P715</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABSA75+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.266Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P716</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABSA110+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.244Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P717</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABSA200+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.216Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P718</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABS75+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.197Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P720</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ABS150+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.173Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P721</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ASR2+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.156Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P724</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ASR6+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.139Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P725</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ASR12+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.122Z</lastUpdated>
  </row>
  <row>
    <udiDi>+G306P726</udiDi>
    <basicUdiDi>++G306P7A2</basicUdiDi>
    <tradeName>Kryo Systeme IIa</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Consarctic GmbH</manufacturerName>
    <manufacturerSrn>DE-PR-000020486</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>V0902</emdnCode>
    <emdnDescription>CLINICAL/THERAPEUTIC APPLICATIONS LIQUID NITROGEN</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ASR25+</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-21T21:03:48.110Z</lastUpdated>
  </row>
</eudamedExport>